6 news items
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
NVCR
3 Jun 24
from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
NVCR
2 May 24
results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory
Novocure Reports First Quarter 2024 Financial Results
NVCR
2 May 24
-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks
Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
NVCR
24 Apr 24
-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
NVCR
5 Apr 24
reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific
arms8iiq1qnkp6cbb
NVCR
27 Mar 24
financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those
- Prev
- 1
- Next